Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Neoplasm Metastasis 1Mesothelioma, Malignant 1Lymphoma 1

Interventions

Pemetrexed 9Cisplatin 9pembrolizumab 5defactinib 3Cyclophosphamide 3sodium thiosulfate 2Radiotherapy, Intensity-Modulated 2Platinum 2Immunoenzyme Techniques 2Doxorubicin 21,2-diaminocyclohexaneplatinum II citrate 2vatalanib 1spartalizumab 1osimertinib 1nintedanib 1liposomal doxorubicin 1cabozantinib 1antineoplaston AS 2-1 1antineoplaston A10 1amatuximab 1alvocidib 1aldesleukin 1X-Rays 1VS-5584 1Trabectedin 1Tetrahydrouridine 1Specimen Handling 1Ramucirumab 1Radiotherapy 1Radiation Dose Hypofractionation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Mesothelioma, Malignant × VS-5584 × Clear all
NCT02372227 2017-01-30

A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma

Verastem, Inc.

Phase 1 Terminated
21 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡